Opaleye Management’s Edgewise Therapeutics EWTX Stock Holding History

Opaleye Management’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.3M	Hold	500,000	–	–	1.84%	15
2026 Q1	$15.8M	Hold	500,000	–	–	2.07%	16
2025 Q4	$12.4M	Hold	500,000	–	–	1.64%	18
2025 Q3	$8.11M	Buy	500,000 +10,000	+2%	+$142K	1.15%	20
2025 Q2	$6.42M	Buy	490,000 +95,000	+24%	+$1.37M	1.3%	17
2025 Q1	$8.69M	Sell	395,000 -85,000	-18%	-$2.23M	1.93%	11
2024 Q4	$12.8M	Sell	480,000 -42,500	-8%	-$1.35M	2.24%	10
2024 Q3	$13.9M	Sell	522,500 -57,500	-10%	-$1.14M	2.33%	11
2024 Q2	$10.4M	Sell	580,000 -85,000	-13%	-$1.48M	2.39%	10
2024 Q1	$12.1M	Sell	665,000 -34,000	-5%	-$540K	2.64%	10
2023 Q4	$7.65M	Sell	699,000 -176,405	-20%	-$1.24M	2.03%	14
2023 Q3	$5.02M	Buy	875,405 +60,405	+7%	+$411K	1.63%	14
2023 Q2	$6.32M	Buy	815,000 +65,000	+9%	+$548K	1.51%	17
2023 Q1	$5M	Buy	750,000 +138,600	+23%	+$1.28M	1.5%	22
2022 Q4	$5.47M	Sell	611,400 -23,600	-4%	-$221K	1.9%	16
2022 Q3	$6.25M	Buy	635,000 +183,600	+41%	+$1.86M	2.58%	12
2022 Q2	$3.59M	Buy	451,400 +148,400	+49%	+$1.12M	1.62%	20
2022 Q1	$2.94M	Buy	+303,000	New	+$3.9M	0.91%	30

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management's EWTX Position: Q2 2026 in Review

Opaleye Management held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 500,000 shares worth $20.3M. The position accounts for 1.84% of the portfolio, ranked #15.

Opaleye Management first reported a position in EWTX in Q1 2022 and has held it in 18 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Opaleye Management held 500,000 shares of Edgewise Therapeutics worth $20.3M as of Q2 2026.
Opaleye Management left its Edgewise Therapeutics share count unchanged in Q2 2026.
Edgewise Therapeutics made up 1.84% of Opaleye Management's portfolio in Q2 2026, its #15 holding.
Opaleye Management first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 18 quarters since.
226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.